Elicio Therapeutics, Inc. (ELTX)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 15M 30M 45M Q4 '20: 2.9M Q1 '21: 2.4M Q2 '21: 2.2M Q3 '21: 2.8M Q4 '21: 28.3M Q1 '22: 29.6M Q2 '22: 29.7M Q3 '22: 28.2M Q4 '22: 2.3M Q1 '23: 653K Q1 '21 Q3 '21 Q1 '22 Q3 '22 Q1 '23

Gross Profit TTM

0 10M 20M 30M Q4 '20: 1.7M Q1 '21: 1.6M Q2 '21: 1.7M Q3 '21: 2.7M Q4 '21: 27.9M Q4 '20 Q1 '21 Q2 '21 Q3 '21 Q4 '21

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income TTM

-75M -50M -25M 0 25M 50M 75M Q4 '20: -55.3M Q1 '21: -62.6M Q2 '21: -63.6M Q3 '21: -67.8M Q4 '21: -39.3M Q1 '22: -33.9M Q2 '22: -21.8M Q3 '22: -11.9M Q4 '22: -32.4M Q1 '23: -25.8M Q2 '23: -27.3M Q3 '23: -32.3M Q4 '23: -35.7M Q1 '24: -38.2M Q2 '24: -41.3M Q3 '24: -40.9M Q4 '24: -45M Q1 '25: -45.5M Q2 '25: -44.6M Q3 '25: -42.3M Q4 '25: -37.7M Q1 '26: -37.6M Q2 '26: -37.9M Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income TTM

-120M -80M -40M 0 40M 80M 120M Q4 '20: -80.1M Q1 '21: -103.6M Q2 '21: -100.3M Q3 '21: -98.3M Q4 '21: -54.6M Q1 '22: -24.9M Q2 '22: -15.2M Q3 '22: -6.7M Q4 '22: -28.2M Q1 '23: -29.2M Q2 '23: -29.4M Q3 '23: -32.9M Q4 '23: -35.2M Q1 '24: -39M Q2 '24: -38.7M Q3 '24: -46.8M Q4 '24: -51.9M Q1 '25: -51.3M Q2 '25: -54.6M Q3 '25: -45.9M Q4 '25: -39.6M Q1 '26: -40.2M Q2 '26: -37.8M Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue TTM

0 500K 1M 1.5M Q4 '20: 1.2M Q1 '21: 807K Q2 '21: 474K Q3 '21: 126K Q4 '21: 433K Q4 '20 Q1 '21 Q2 '21 Q3 '21 Q4 '21

Operating Cash Flow TTM

-60M -40M -20M 0 20M 40M 60M Q4 '20: -22.9M Q1 '21: -26.7M Q2 '21: -24.4M Q3 '21: -17.7M Q4 '21: -52.6M Q1 '22: -55.7M Q2 '22: -39.1M Q3 '22: -29.3M Q4 '22: -22.2M Q1 '23: -14.7M Q2 '23: -30.3M Q3 '23: -30.1M Q4 '23: -32.7M Q1 '24: -36.7M Q2 '24: -36.1M Q3 '24: -38.2M Q4 '24: -37.1M Q1 '25: -35.1M Q2 '25: -35.1M Q3 '25: -38.9M Q4 '25: -37M Q1 '26: -38.5M Q2 '26: -37.7M Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow TTM

-60M -40M -20M 0 20M 40M 60M Q4 '20: -22.9M Q1 '21: -26.8M Q2 '21: -24.7M Q3 '21: -18M Q4 '21: -53M Q1 '22: -56.1M Q2 '22: -39.7M Q3 '22: -29.9M Q4 '22: -22.8M Q1 '23: -15.3M Q2 '23: -30.4M Q3 '23: -30.2M Q4 '23: -32.8M Q1 '24: -36.7M Q2 '24: -36.2M Q3 '24: -38.3M Q4 '24: -37.2M Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 15M 30M 45M Q1 '20: 14.5M Q2 '20: 14.5M Q3 '20: 14.8M Q1 '21: 23.4M Q2 '21: 29.7M Q3 '21: 29.8M Q1 '22: 30M Q2 '22: 314.6K Q3 '22: 317.5K Q1 '23: 324.1K Q2 '23: 2.9M Q3 '23: 8.4M Q1 '24: 10.3M Q2 '24: 11.3M Q3 '24: 13.6M Q1 '25: 13M Q2 '25: 16.1M Q3 '25: 16.7M Q1 '26: 18.2M Q2 '26: 19.2M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-105.00 -70.00 -35.00 0.00 35.00 70.00 105.00 Q4 '20: -5.42 Q1 '21: -6.07 Q2 '21: -5.25 Q3 '21: -4.59 Q4 '21: -1.93 Q1 '22: -0.85 Q2 '22: -23.47 Q3 '22: -45.61 Q4 '22: -67.10 Q1 '23: -91.39 Q2 '23: -70.80 Q3 '23: -49.40 Q4 '24: -4.20 Q1 '25: -3.92 Q2 '25: -3.94 Q3 '25: -3.15 Q4 '25: -2.62 Q1 '26: -2.40 Q2 '26: -2.17 Q4 '20 Q3 '21 Q2 '22 Q1 '23 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.